The FDA has approved Camcevi ETM, a long-acting formulation of leuprolide mesylate, for the treatment of advanced prostate cancer.

The ArteraAI Prostate Test is intended to assist clinicians and patients with risk-based decisions in localized prostate cancer.

Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer.

The FDA’s De Novo authorization for the tool establishes a new product code category for future AI-powered digital pathology risk-stratification tools.

A new study offers insights into what type of cancer treatment may be best for gay men, depending on their sexual preferences. A new study offers insights into what type of cancer treatment may be ...

September is Prostate Cancer Awareness Month, yet too many men will let it pass without notice. Prostate cancer is the second most common cancer in men in the United States, ...

About 16% of men designated GG1 prostate cancer had higher-risk disease, raising their likelihood of dying from the cancer and undermining efforts to reclassify this grade as noncancerous.

The Food and Drug Administration has granted Fast Track designation to HLD-0915 for the treatment of patients with metastatic castration-resistant prostate cancer.

A preclinical evaluation of a new 'dual-mode' tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and ...

The identification of RSPO2 as a key driver of disease progression opens new possibilities for treatment strategies aimed at improving outcomes for patients with advanced prostate cancer.